Is a severely damaged Biogen looking to shed its ties to a controversial development partner?
After taking it on the chin throughout Thursday and Friday for its questionable strategy of sticking with the amyloid beta theory on Alzheimer’s …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
